Maintaining a Hold rating on Larimar Therapeutics due to early-stage development of nomlabofusp for Friedreich’s ataxia and uncertainty about its functional benefits. The stock has dropped over ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback